Schistosomiasis is a chronic condition and one of the most common and most devastating parasitic diseases in tropical countries. It is estimated that more than 200 million people are infected worldwide and that around 280,000 die from it each year. Flatworms transmit the disease. It is widespread in tropical and subtropical regions where large sections of the populations have no access to clean water and sanitary installations. People become infected with the parasite via contact with freshwater, for example while working, swimming, fishing or washing their clothes. The miniscule larvae penetrate human skin, enter the blood vessels and attack internal organs. The infection rate is particularly high among school-aged children. Praziquantel is the only active ingredient with which all forms of schistosomiasis can be treated. WHO has therefore deemed praziquantel, the most cost-efficient solution for the health of patients in need, as the drug of choice.
About the Praziquantel Donation Program from Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, initiated the Praziquantel Donation Program in cooperation with WHO back in 2007. Since then, nearly 700 million tablets have been donated and over 150 million patients treated, mainly school children. Merck KGaA, Darmstadt, Germany, has committed itself to maintaining its efforts in the fight against the tropical disease until schistosomiasis has been eliminated. To this end, each year the company is donating up to 250 million tablets to WHO. The planned annual donation has a value of US$ 27.5 million. In addition, Merck KGaA, Darmstadt, Germany, is supporting awareness programs at schools in Africa in order to educate children about the causes of schistosomiasis and ways to prevent it. Furthermore, as part of a public-private partnership, the company is researching a new formulation of praziquantel that can also be administered to very young children. To date, the tablets are only suitable for children older than six.
About NALA Foundation
Since 2008, NALA (NTD Advocacy, Learning, Action) has worked to eliminate Neglected Tropical Diseases (NTDs) in Ethiopia. To date, NALA’s work has led to a drastic reduction in disease prevalence of schistosomiasis and intestinal worms in project areas. Their holistic model achieves sustainable and measurable results in NTD elimination by complementing mass drug administration with intensive health education, community mobilization, and community-led improvements to water, sanitation and hygiene (WASH). NALA’s health education and community campaigns focus on school children and women as the primary messengers of change in health practices for the family. NALA also trains and supports local partners, stakeholders, and community volunteers to lead and continue these efforts.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.